Rational Design of Autotaxin Inhibitors by Structural Evolution of Endogenous Modulators.


Autotaxin produces the bioactive lipid lysophosphatidic acid (LPA) and is a drug target of considerable interest for numerous pathologies. We report the expedient, structure-guided evolution of weak physiological allosteric inhibitors (bile salts) into potent competitive Autotaxin inhibitors that do not interact with the catalytic site. Functional data confirms that our lead compound attenuates LPA mediated signaling in cells and reduces LPA synthesis in vivo, providing a promising natural product derived scaffold for drug discovery.

More about this publication

Journal of medicinal chemistry
  • Volume 60
  • Issue nr. 5
  • Pages 2006-2017
  • Publication date 09-03-2017

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.